Strategic Partnerships Leverage Aptar Digital Health's collaborations with Enable Injections, ŌURA, AstraZeneca, Biogen, and QoL Geneva to position Cohero Health as a preferred digital health platform for pharma and device partnerships, enabling real-world data sharing, AI-enabled screening, and enhanced patient adherence across respiratory and neurological indications.

Clinical Adoption Readiness The platform's real-time adherence tracking, lung function data, and cross-device mobile app align with payer and provider demand for remote monitoring and outcomes-based care, creating opportunities to sell to hospitals, health systems, and insurers seeking measurable ROI.

Product Expansion The existing hardware and software suite—inhaler sensors, mobile spirometers, and a cross-platform app—offers expansion into asthma and COPD markets and can be extended to self-injectable therapies through partnerships with device manufacturers.

Global Collaboration International collaborations and university research partnerships demonstrate readiness to deploy across regions, making the platform attractive to multinational pharma, CROs, and health systems pursuing global digital health programs.

Monetization Pathways With a focused growth plan, opportunities include licensing AI-powered screening, co-development with pharma, white-labeling the platform, and delivering data analytics services for clinical trials and post-market surveillance.